Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG4 response

Background: BM32, a grass pollen allergy vaccine containing four recombinant fusion proteins consisting of hepatitis B-derived PreS and hypoallergenic peptides from the major timothy grass pollen allergens adsorbed on aluminium hydroxide has been shown to be safe and to improve clinical symptoms of...

Full description

Bibliographic Details

Published in:	EBioMedicine
Main Authors:	Julia Eckl-Dorna, Milena Weber, Victoria Stanek, Birgit Linhart, Robin Ristl, Eva E. Waltl, Sergio Villazala-Merino, Andrea Hummel, Margarete Focke-Tejkl, Renate Froeschel, Angela Neubauer, Rainer Henning, Thomas Perkmann, Rudolf Valenta, Verena Niederberger
Format:	Article
Language:	English
Published:	Elsevier 2019-12-01
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352396419307479